High-Risk Adults
Pfizer Secures FDA Approval to Expand RSV Vaccine Abrysvo for High-Risk Adults Aged 18-59
Pfizer, RSV vaccine, Abrysvo, FDA approval, high-risk adults, immunocompromised adults
Actionable Insights Powered by AI
Pfizer, RSV vaccine, Abrysvo, FDA approval, high-risk adults, immunocompromised adults